AIM: To investigate the QT/QTc effects of orally administered moxifloxacin in healthy Chinese volunteers. METHODS: This was a single-blinded, randomized, single-dose, placebo-controlled, two-period cross-over study. A total of 24 healthy Chinese volunteers were enrolled, randomly assigned to two groups: one group received moxifloxacin (400 mg, po) followed by placebo with a 7-d interval, another group received placebo followed by moxifloxacin with a 7-d interval. On the days of dosing, 12-lead 24 h Holter ECGs were recorded and evaluated by an ECG laboratory blind to the treatments. Blood samples were collected to determine plasma concentrations of moxifloxacin. RESULTS: The orally administered moxifloxacin significantly prolonged the mean QTc at all time points except 0.5 h post-dose. The largest time-matched difference in the QTcI was 8.35 ms (90% CI: 5.43, 11.27) at 4 h post-dose. The peak effect on QTcF was 9.35 ms (90% CI: 6.36, 12.34) at 3 h post-dose. A pharmacokinetic-QTc model suggested a 2.084 ms increase in the QTc interval for every 1000 ng/mL increase in plasma concentration of moxifloxacin. In addition, the orally administered moxifloxacin was well tolerated by the subjects. CONCLUSION: Orally administered moxifloxacin significantly prolongs QTc, which supports its use as a positive control in ICH-E14 TQT studies in Chinese volunteers.
RCT Entities:
AIM: To investigate the QT/QTc effects of orally administered moxifloxacin in healthy Chinese volunteers. METHODS: This was a single-blinded, randomized, single-dose, placebo-controlled, two-period cross-over study. A total of 24 healthy Chinese volunteers were enrolled, randomly assigned to two groups: one group received moxifloxacin (400 mg, po) followed by placebo with a 7-d interval, another group received placebo followed by moxifloxacin with a 7-d interval. On the days of dosing, 12-lead 24 h Holter ECGs were recorded and evaluated by an ECG laboratory blind to the treatments. Blood samples were collected to determine plasma concentrations of moxifloxacin. RESULTS: The orally administered moxifloxacin significantly prolonged the mean QTc at all time points except 0.5 h post-dose. The largest time-matched difference in the QTcI was 8.35 ms (90% CI: 5.43, 11.27) at 4 h post-dose. The peak effect on QTcF was 9.35 ms (90% CI: 6.36, 12.34) at 3 h post-dose. A pharmacokinetic-QTc model suggested a 2.084 ms increase in the QTc interval for every 1000 ng/mL increase in plasma concentration of moxifloxacin. In addition, the orally administered moxifloxacin was well tolerated by the subjects. CONCLUSION: Orally administered moxifloxacin significantly prolongs QTc, which supports its use as a positive control in ICH-E14 TQT studies in Chinese volunteers.
Authors: Gan-Xin Yan; Ramarao S Lankipalli; James F Burke; Simone Musco; Peter R Kowey Journal: J Am Coll Cardiol Date: 2003-08-06 Impact factor: 24.094
Authors: James P Tsikouris; Michael J Peeters; Craig D Cox; Gary E Meyerrose; Charles F Seifert Journal: Ann Noninvasive Electrocardiol Date: 2006-01 Impact factor: 1.468
Authors: Sanjeev Khindri; Ronald Sabo; Stuart Harris; Ralph Woessner; Simon Jennings; Anton F Drollmann Journal: BMC Pulm Med Date: 2011-05-26 Impact factor: 3.317
Authors: Simone H J van den Elsen; Marieke G G Sturkenboom; Onno W Akkerman; Katerina Manika; Ioannis P Kioumis; Tjip S van der Werf; John L Johnson; Charles Peloquin; Daan J Touw; Jan-Willem C Alffenaar Journal: Antimicrob Agents Chemother Date: 2019-06-24 Impact factor: 5.191
Authors: Jorg Taubel; Dominic Pimenta; Samuel Thomas Cole; Claus Graff; Jørgen K Kanters; A John Camm Journal: Clin Res Cardiol Date: 2022-05-21 Impact factor: 6.138